StockNews.com Upgrades BioLineRx (NASDAQ:BLRX) to Hold

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRXGet Rating) from a sell rating to a hold rating in a research note published on Monday.

Shares of BioLineRx stock opened at $1.34 on Monday. The company has a market cap of $63.90 million, a price-to-earnings ratio of -2.39 and a beta of 2.01. BioLineRx has a 1 year low of $1.01 and a 1 year high of $3.62. The company’s fifty day simple moving average is $1.35 and its 200-day simple moving average is $1.67.

BioLineRx (NASDAQ:BLRXGet Rating) last issued its earnings results on Wednesday, May 11th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.05. On average, analysts anticipate that BioLineRx will post -0.51 earnings per share for the current year.

Hedge funds have recently modified their holdings of the stock. Schonfeld Strategic Advisors LLC bought a new position in BioLineRx in the third quarter worth $33,000. Geneos Wealth Management Inc. lifted its holdings in shares of BioLineRx by 63.1% during the fourth quarter. Geneos Wealth Management Inc. now owns 28,950 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 11,200 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of BioLineRx by 377.6% during the first quarter. Renaissance Technologies LLC now owns 67,346 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 53,246 shares during the period. Atria Wealth Solutions Inc. bought a new position in shares of BioLineRx during the first quarter valued at $178,000. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of BioLineRx by 184.7% during the fourth quarter. Envestnet Asset Management Inc. now owns 122,224 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 79,296 shares during the period. 5.23% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx (Get Rating)

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Featured Stories

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.